19125-34-9

Basic information

• Product Name: 1-N-PHENYL-PIPERIDIN-4-ONE
• Synonyms: 1-N-PHENYL-PIPERIDIN-4-ONE;1-PHENYLPIPERIDIN-4-ONE ;1-phenylpiperidin-4-one(SALTDATA: FREE);N-phenylpiperidin-4-one;1-Phenyl-4-piperidone;N-Phenyl-4-piperidone;4-Piperidinone,1-phenyl-
• CAS NO: 19125-34-9
• Molecular Formula: C₁₁H₁₃NO
• Molecular Weight: 175.23
• Product Categories: CHIRAL CHEMICALS
• Mol File: 19125-34-9.mol
• Article Data: 21

Chemical Properties

• Melting Point: 36.5-37.2℃
• Boiling Point: 312.9°Cat760mmHg
• Flash Point: 124.1°C
• Appearance: /
• Density: 1.107g/cm³
• Vapor Pressure: 1.45E-05mmHg at 25°C
• Refractive Index: 1.56
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 1-N-PHENYL-PIPERIDIN-4-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-N-PHENYL-PIPERIDIN-4-ONE(19125-34-9)
• EPA Substance Registry System: 1-N-PHENYL-PIPERIDIN-4-ONE(19125-34-9)

Safety Data

• Hazardous Substances Data: 19125-34-9(Hazardous Substances Data)

Usage

Description

1-N-PHENYL-PIPERIDIN-4-ONE is an organic compound that serves as a crucial intermediate in the synthesis of various pharmaceutical compounds. It is characterized by its unique molecular structure, which features a phenyl group attached to a piperidine ring with a ketone functional group at the 4-position. This structure endows it with specific chemical properties that make it valuable in the development of medications targeting specific receptors.

Uses

Used in Pharmaceutical Industry:
1-N-PHENYL-PIPERIDIN-4-ONE is used as a reagent for the preparation of isoteric N-arylpiperazine derivatives. These derivatives are known as dihydropyridine NPY1 receptor antagonists, which play a significant role in the development of medications for various therapeutic applications.
In the context of the provided materials, 1-N-PHENYL-PIPERIDIN-4-ONE is specifically utilized in the synthesis of dihydropyridine NPY1 receptor antagonists. These antagonists are of interest due to their potential applications in treating conditions such as obesity, anxiety, and depression by targeting the neuropeptide Y1 receptor. The compound's unique structure allows for the development of selective and potent antagonists, which can be further optimized for improved pharmacological properties and therapeutic efficacy.

InChI:InChI=1/C11H13NO/c13-11-8-4-5-9-12(11)10-6-2-1-3-7-10/h1-3,6-7H,4-5,8-9H2

Upstream product

• 92246-21-4 4-oxo-1-phenyl-piperidine-3-carboxylic acid ethyl ester 
• 3592-25-4 1,5-dichloropentan-3-one 
• 62-53-3 aniline 
• 7564-64-9 3-methyl-1,3,5-pentanetriol 
• 177-11-7 4,4-ethylenedioxy-piperidine 
• 460-00-4 1-Bromo-4-fluorobenzene 
• 140200-76-6 α,α'-dibromopentan-3-one 
• 108-86-1 bromobenzene 
• 591-50-4 iodobenzene 
• 77542-27-9 1-benzyl-1-methyl-4-oxopiperidin-1-ium iodide salt 
• 170011-70-8 1-(4-amino-phenyl)-piperidin-4-one 
• 52409-22-0 tris-(dibenzylideneacetone)dipalladium⁽⁰⁾ 
• 865-48-5 sodium t-butanolate 
• 72548-31-3 1,5-Dichloropentan-3-ol 

Downstream Products

• 125138-08-1 1-phenyl-4-(carboethoxymethylene)piperidine 
• 125138-07-0 2-(1-phenylpiperidin-4-ylidene)acetonitrile 
• 154913-13-0 1-Phenyl-4-(1-naphthyl)-4-piperidinol 
• 125138-04-7 1-phenyl-4-(phenylmethylene)piperidine 
• 125138-05-8 1-phenyl-4-<(p-cyanophenyl)methylene>piperidine 
• 125138-06-9 1-phenyl-4-(1-naphthylmethylene)piperidine 
• 91759-52-3 4-<(1-Phenyl-4-piperidinylidene)methyl>-1-naphthalenecarbonitrile 
• 125138-09-2 1-phenyl-4-<(pentafluorophenyl)methylene>piperidine 
• 125138-10-5 1-phenyl-4-<<3,5-bis(trifluoromethyl)phenyl>methylene>piperidine 
• 111153-74-3 4-formyl-1-phenylpiperidine 
• 91759-51-2 1-phenyl-4-<(2-naphthyl)methylene>piperidine 
• 112166-49-1 N-Phenyl-4-azacyclohexylidenemalononitrile 
• 125138-03-6 1-Phenyl-4-<methylene>piperidine 
• 7402-94-0 1-phenyl-piperidin-4-one oxime 

Relevant articles and documents

Synthesis method of intermediate N-phenyl-4-piperidone

The invention discloses a synthesis method of an intermediate N-phenyl-4-piperidone, which comprises the following steps: dissolving aniline in diethyl ether, adding a catalyst, adding 3-methyl-1,3,5-pentanetriol under stirring, heating the raw material t

Dual C(sp3)?H Bond Functionalization of N-Heterocycles through Sequential Visible-Light Photocatalyzed Dehydrogenation/[2+2] Cycloaddition Reactions

Herein we describe a mild method for the dual C(sp3)?H bond functionalization of saturated nitrogen-containing heterocycles through a sequential visible-light photocatalyzed dehydrogenation/[2+2] cycloaddition procedure. As a complementary approach to the well-established use of iminium ion and α-amino radical intermediates, the elusive cyclic enamine intermediates were effectively generated by photoredox catalysis under mild conditions and efficiently captured by acetylene esters to form a wide array of bicyclic amino acid derivatives, thus enabling the simultaneous functionalization of two vicinal C(sp3)?H bonds.

Fused tricyclic hepatitis virus inhibitor and application thereof

The invention belongs to the field of medical chemistry, relates to a fused tricyclic hepatitis virus inhibitor and application thereof, and particularly, provides a compound of the general formula I or pharmaceutically acceptable salt, isomer, solvate, crystal or prodrug thereof, and a medicine composition containing the compounds and application of the compounds or the composition in medicine preparation. The compound has the good inhibiting activity on hepatitis C virus, meanwhile has the low toxicity on host cells, and is high in effectiveness, good in safety and likely to become the medicine for treating and/or preventing diseases relevant to HCV infection.